2188211-90-5
2188211-90-5
Chemical Structure
CYP8B1-IN-1
- CAS No.: 2188211-90-5
- Formula:C23H21ClF3N7O
- Molecular Weight:503.91
InChIKey: UHHUWELHMBITRT-CJNGLKHVSA-N
SMILES: C[C@@H]1CN(C2=C(C#N)C=NC3=CC=C(Cl)C=C32)CC[C@@H]1C(N4CCN5C(C4)=NN=C5C(F)(F)F)=O
Biological Activity: CYP8B1-IN-1 is an orally active CYP8B1 inhibitor (human IC50 = 0.4 nM; mouse IC50 = 0.5 nM). CYP8B1-IN-1 acts by inhibiting cytochrome P450 (Cytochrome P450) 8B1-mediated 12α-hydroxylation in Cholic acid (HY-N0324) synthesis and is selective over other CYP isoforms. CYP8B1-IN-1 can be used in research on non-alcoholic fatty liver disease, type 2 diabetes, and metabolic diseases[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
CYP8B1-IN-1 | CYP8B1-IN-1 is an orally active CYP8B1 inhibitor (human IC50 = 0.4 nM; mouse IC50 = 0.5 nM). CYP8B1-IN-1 acts by inhibiting cytochrome P450 (Cytochrome P450) 8B1-mediated 12α-hydroxylation in Cholic acid (HY-N0324) synthesis and is selective over other CYP isoforms. CYP8B1-IN-1 can be used in research on non-alcoholic fatty liver disease, type 2 diabetes, and metabolic diseases. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
